Market News AIOpen the app

Evaxion Reports Phase II Results for EVX-01 in Advanced Melanoma

TrialRead the original at tradingview.com
Good for EVAX

Evaxion reported a 75% response rate and lasting immune activity with EVX-01 and pembrolizumab. These findings favor the company's outlook, though the study included few patients.

EVAX · Evaxion Biotech

AI read · Good for EVAX

The AI's read

The findings give Evaxion early evidence that its vaccine may help patients when paired with an existing cancer drug. Continued immune activity adds support. The study was small, so the result may not hold in a larger group.

Get alerts for EVAX

Follow Evaxion Biotech (EVAX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EVAX
Free on the App Store and Google Play, or on the web.